Mod GRF 1-29
Also known as: CJC-1295 without DAC, CJC-1295 no DAC, CJC1295 no DAC, Modified GRF 1-29, ModGRF1-29, Mod-GRF 1-29, Mod GRF (1-29), tetrasubstituted GRF(1-29)
Growth Hormone-Releasing Hormone (GHRH) Analogue / Growth Hormone Secretagogue
What it is
Mod GRF 1-29, also called CJC-1295 without DAC, is a peptide people use to trigger short bursts of their own growth hormone, usually alongside a GHRP such as ipamorelin. It is a modified, more stable version of the natural hormone signal (GHRH 1-29) and lasts about 30 minutes in the body, so it is injected one to three times a day rather than weekly. Not FDA-approved; banned by WADA.
The scientific side
Mod GRF 1-29 (CJC-1295 without DAC) is a synthetic analogue of human growth hormone-releasing hormone (GHRH 1-29) with four amino-acid substitutions (D-Ala2, Gln8, Ala15, Leu27) that make it resistant to dipeptidylpeptidase-IV cleavage and more stable than native GHRH(1-29) (sermorelin). It acts as a GHRH receptor agonist on anterior pituitary somatotrophs, producing a pulse of GH release and downstream IGF-1. Unlike CJC-1295 with DAC, it carries no Drug Affinity Complex, so it does not bind serum albumin: its half-life is roughly 30 minutes rather than days, and GH release stays pulsatile. The half-life and dosing data in the published CJC-1295 trials describe the DAC form and do not apply to Mod GRF 1-29. It is commonly paired with a GHRP (ghrelin-receptor agonist such as ipamorelin, GHRP-2 or GHRP-6), which acts on a separate receptor and amplifies the GH pulse.
Class: Growth Hormone-Releasing Hormone (GHRH) Analogue / Growth Hormone Secretagogue
At a glance
| What it is | GRF(1-29), the active piece of growth hormone-releasing hormone, with four amino acids swapped to resist breakdown. Often sold as "CJC-1295 without DAC". |
|---|---|
| FDA status | Not approved for any use. Not named on FDA's compounding safety-risk page; an FDA advisory committee voted against the non-DAC forms of CJC-1295 in 2024. |
| Used for | Short growth hormone pulses, usually injected daily before bed and often paired with a GHRP. |
| Human evidence | None published for Mod GRF 1-29 itself. |
| Half-life | Not published. It is expected to be short, like sermorelin, but this has not been measured. |
| Banned in sport | Yes, as a GHRH analogue under WADA S2.2.4, prohibited at all times. |
What is Mod GRF 1-29?
Mod GRF 1-29 ("modified GRF 1-29") is the first 29 amino acids of growth hormone-releasing hormone, the same sequence as Sermorelin, with four amino acids substituted. The changes are usually listed as D-Ala2, Gln8, Ala15 and Leu27. Researchers describe this backbone as "tetrasubstituted" GRF(1-29).
It is the core of CJC-1295 without the albumin-binding DAC group, which is why vendors also call it "CJC-1295 without DAC" or "CJC-1295 no DAC". Check labels carefully: the two products are dosed and behave very differently.
How does it work?
Like sermorelin, it binds GHRH receptors on the pituitary to trigger a pulse of the body's own growth hormone.
The substitutions target the reason native GRF is so short-lived: an enzyme in plasma, DPP-IV, inactivates GRF by cutting the bond after position 2. Analog work in the 1990s showed that changing position 2 (and position 15) made GRF far more stable in plasma and more active in animals. How long Mod GRF 1-29 itself lasts in people has not been published.
Pharmacokinetics
| Half-life | Not published for Mod GRF 1-29 |
|---|---|
| Metabolism | Designed to resist DPP-IV, the plasma enzyme that inactivates native GRF |
| Clearance | Not characterized |
| Route | Sold for injection under the skin; no human route studies |
Is it FDA-approved?
No. It has never been approved for any use, and no company has run trials of it.
FDA's page of compounding substances with significant safety risks does not name Mod GRF 1-29. In December 2024, FDA's Pharmacy Compounding Advisory Committee voted against the non-DAC forms of CJC-1295 for the 503A bulks list (0-13 for the free base, 1-12 for the acetate), along with the DAC forms.
- WADA: S2.2.4 Growth hormone releasing factors (covered as a GHRH analogue; prohibited at all times)
History
Its history runs through two other peptides. Sermorelin (GRF 1-29) was an approved drug from 1990 to 2008, but native GRF breaks down within minutes. In the early 1990s, researchers made substituted GRF(1-29) analogs that resisted plasma enzymes.
ConjuChem used a tetrasubstituted GRF(1-29) as the base for CJC-1295, adding the DAC group to bind albumin. The backbone without DAC was never developed as a drug; it reached the market through research-peptide vendors, which is where the "Mod GRF 1-29" and "CJC-1295 no DAC" names come from.
Regulatory timeline
Side effects
There are no published human side-effect data for Mod GRF 1-29. Side effects reported for related GHRH analogs include injection-site reactions and facial flushing (sermorelin), and raised blood sugar and fluid retention (tesamorelin), but those are different drugs.
Because it raises growth hormone, the same cautions apply as for other GHRH analogs: people with active cancer or pituitary disease should not use it without medical advice.
Who should not use it
- No established contraindications: Mod GRF 1-29 has never been studied in humans.
- Competitive athletes: Prohibited at all times under WADA S2.2.4 (growth hormone releasing factors), per the 2026 World Anti-Doping Code Prohibited List. Verified against the current WADA list as of October 2026.
- Active cancer or pituitary disease: it raises growth hormone and IGF-1.
- Pregnancy and breastfeeding: not studied.
No published human data for Mod GRF 1-29.
What does the research show?
No clinical trial or published human study has tested Mod GRF 1-29. A 2026 review of performance-enhancing GH peptides describes the gap between this kind of self-administration and the clinical evidence.
The closest evidence is indirect: sermorelin raised growth hormone and, at twice-daily doses, IGF-1 in older adults; and CJC-1295 with DAC, which shares its backbone, raised growth hormone and IGF-1 in healthy adults. Neither tells you the effect, dose or half-life of Mod GRF 1-29.
Studied for
- No human studies published
- Related analogs: GRF(1-29) stability in plasma and GH release in animals (1990s)
FAQ
Is Mod GRF 1-29 the same as CJC-1295?
Not quite. It is the same backbone without the DAC group. CJC-1295 with DAC binds albumin and lasts about a week; Mod GRF 1-29 does not.
Sources: [1]
Has Mod GRF 1-29 been tested in humans?
No published human study exists. Claims about its effects are extrapolated from sermorelin and CJC-1295.
Sources: [8]
What is its half-life?
It has not been published. It is often quoted as about 30 minutes online, but no peer-reviewed study has measured it.
Is Mod GRF 1-29 FDA-approved?
No. FDA's advisory committee voted against the non-DAC forms of CJC-1295 for compounding in December 2024.
Sources: [5]
Why is it paired with Ipamorelin?
They act on different receptors: Mod GRF 1-29 on the GHRH receptor and Ipamorelin on the ghrelin receptor. No published trial has tested the combination.
Sources: [11]
Is Mod GRF 1-29 banned in sport?
Yes. WADA S2.2.4 covers growth hormone-releasing hormone and its analogues, prohibited at all times.
Sources: [12]
Citations
- Jetté L, et al. hGRF1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology 2005. PMID 15817669
- Memdouh S, et al. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Test Anal 2021. PMID 34665524
- Kubiak TM, et al. Position 2 and position 2/Ala15-substituted analogs of bovine GRF with enhanced metabolic stability and improved in vivo bioactivity. J Med Chem 1993. PMID 8464043
- FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- FDA: final summary minutes of the Pharmacy Compounding Advisory Committee meeting, December 4, 2024. fda.gov/media/185642/download
- Prakash A, Goa KL. Sermorelin: a review of its use in children with idiopathic growth hormone deficiency. BioDrugs 1999. PMID 18031173
- EGRIFTA SV (tesamorelin) for injection, prescribing information, DailyMed (current label). dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224
- Dominikowski A, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis. Front Endocrinol 2026. PMID 42395176
- Teichman SL, et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab 2006. PMID 16352683
- Corpas E, et al. GHRH-(1-29) twice daily reverses the decreased GH and IGF-I levels in old men. J Clin Endocrinol Metab 1992. PMID 1379256
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998. PMID 9849822
- World Anti-Doping Agency: Prohibited List 2026 (copy hosted by SEGAS). segas.gr/wp-content/uploads/2025/11/2026list_en_final_clean_september_2025.pdf
Sources
- Kubiak 1993. Kubiak TM, et al. Position 2 and position 2/Ala15-substituted analogs of bovine GRF with enhanced metabolic stability and improved in vivo bioactivity. J Med Chem 1993. pubmed.ncbi.nlm.nih.gov/8464043
- Jetté 2005. Jetté L, et al. hGRF1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology 2005. pubmed.ncbi.nlm.nih.gov/15817669
- Memdouh 2021. Memdouh S, et al. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Test Anal 2021. pubmed.ncbi.nlm.nih.gov/34665524
- Dominikowski 2026. Dominikowski A, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis. Front Endocrinol 2026. pubmed.ncbi.nlm.nih.gov/42395176
- Teichman 2006. Teichman SL, et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab 2006. pubmed.ncbi.nlm.nih.gov/16352683
- Corpas 1992. Corpas E, et al. GHRH-(1-29) twice daily reverses the decreased GH and IGF-I levels in old men. J Clin Endocrinol Metab 1992. pubmed.ncbi.nlm.nih.gov/1379256
- Prakash 1999. Prakash A, Goa KL. Sermorelin: a review of its use in children with idiopathic growth hormone deficiency. BioDrugs 1999. pubmed.ncbi.nlm.nih.gov/18031173
- Raun 1998. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998. pubmed.ncbi.nlm.nih.gov/9849822
- DailyMed (Egrifta SV). EGRIFTA SV (tesamorelin) for injection, prescribing information, DailyMed (current label). dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224
- FDA. FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- FDA PCAC, December 2024. FDA: final summary minutes of the Pharmacy Compounding Advisory Committee meeting, December 4, 2024. fda.gov/media/185642/download
- WADA. World Anti-Doping Agency: Prohibited List 2026 (copy hosted by SEGAS). segas.gr/wp-content/uploads/2025/11/2026list_en_final_clean_september_2025.pdf
Administration & storage
- Administration
- Subcutaneous injection (community reports)
- Storage
- No reviewed study describes storage conditions for Mod GRF 1-29.
- Cautions
- CJC-1295 is not approved by any regulatory authority for performance enhancement or general clinical use; human safety data beyond short-term pharmacokinetic studies are lacking.,Potential adverse effects associated with GH-axis modulation (including prolactin/cortisol elevations, appetite changes, dysglycaemia, fluid retention, myalgia/arthralgia, and injection-site reactions) have been reported in the context of GH-axis peptides in this class; specific long-term safety data for CJC-1295 are not available from the reviewed literature.,Products sold outside regulated channels may be mislabelled or contaminated; an illicitly manufactured pharmaceutical preparation containing CJC-1295 was identified by Norwegian police and customs authorities in 2009.,CJC-1295 is classified as a prohibited substance by WADA; use by competitive athletes carries significant anti-doping consequences.,Sterile technique is essential for any injectable compound to minimise infection risk.
Legal & regulatory status
Not approved by the FDA for any indication. Classified as a prohibited performance-enhancing substance by WADA. (PMID: 41966639, 41880199, 31849 — see WADA status below)
Prohibited by the World Anti-Doping Agency (WADA) under Section S2 of the Prohibited List as a growth hormone-releasing hormone analogue.
Not stated in reviewed literature — requires manual verification
Safety signals
- Potential class-level adverse effects of GH-axis secretagogues include prolactin and cortisol elevations, appetite changes, dysglycaemia, fluid retention, musculoskeletal symptoms (myalgia/arthralgia), and injection-site reactions — noted for GH-axis peptides as a group including CJC-1295. PMID 42395176
- Emerging data on GH secretagogues and related peptides used in sport highlight potential risks of cardiovascular strain, insulin resistance, dyslipidaemia, and psychiatric instability, though these are described as a class concern and not specifically quantified for CJC-1295 alone. PMID 41880199
- Indications, dosing, frequency, duration, safety, and efficacy of CJC-1295 for clinical or orthopaedic use remain unknown; significant research is required before definitive recommendations can be made. PMID 41476424
- Non-approved peptides including CJC-1295 lack long-term safety data and systematic validation; significant knowledge gaps include optimal dosing regimens and combination therapy effects. PMID 42021992
- Illicitly manufactured preparations containing CJC-1295 have been identified by law enforcement, raising concerns about product quality, purity, and contamination in the unregulated supply chain. PMID 21204297
- Widespread product mislabelling and contamination have been noted for peptides in the unregulated 'gray market', including CJC-1295; uncertain product composition, dose, and stacking practices increase risk. PMID 42395176
Contraindications
- Use by competitive athletes is prohibited under WADA regulations; competitive athletes are contraindicated from using CJC-1295 outside of an approved therapeutic use exemption. PMID 41138283
- The reviewed literature does not enumerate specific medical contraindications (e.g., pregnancy, malignancy, specific disease states) for CJC-1295. Absence of approval and absence of long-term human safety data preclude clinical use outside of research settings. PMID 41966639
Protocol
100 mcg subcutaneous injection, once daily, pre-sleep. Cycle: 12-16 weeks.
About these dose ranges
Dose ranges below reflect commonly reported community protocols. Where published research cites a specific dose, the PMID is linked. Doses without citations are not clinical recommendations — they reflect what practitioners and researchers commonly report using.
Community-reported dosing
| Route | Dose | Frequency / Duration | Population / context | Source tier |
|---|---|---|---|---|
| subcutaneous injection | 100 mcg | 3x per week (e.g. Mon/Wed/Fri) · 12-16 weeks | biohackers stacking CJC-1295 (no DAC / without DAC) with a GHRP such as GHRP-2 or GHRP-6 or Ipamorelin | [Community] |
| subcutaneous injection | 100 mcg | once daily, pre-sleep · 12-16 weeks | anti-aging and longevity biohackers preferring once-daily simplified stacks | [Community] |
| subcutaneous injection | 100 mcg | 2x daily (morning pre-workout + pre-sleep) · 8-12 weeks | performance-oriented bodybuilders and athletes maximizing GH pulses | [Community] |
| subcutaneous injection | 100 mcg | 3x daily (morning, post-workout, pre-sleep) · 8-12 weeks | advanced bodybuilders running aggressive GH-axis stimulation protocols | [Community] |
| subcutaneous injection | 200 mcg | once daily, pre-sleep · 12-16 weeks | biohackers running moderate-dose CJC-1295 no-DAC solo or stacked with Ipamorelin for sleep and recovery | [Community] |
All studies (7)
- PMID 21204297
Illicitly manufactured preparations containing CJC-1295 have been identified by law enforcement, raising concerns about product quality, purity, and contaminati - PMID 41138283
Use by competitive athletes is prohibited under WADA regulations; competitive athletes are contraindicated from using CJC-1295 outside of an approved therapeuti - PMID 41476424
Indications, dosing, frequency, duration, safety, and efficacy of CJC-1295 for clinical or orthopaedic use remain unknown; significant research is required befo - PMID 41880199
Emerging data on GH secretagogues and related peptides used in sport highlight potential risks of cardiovascular strain, insulin resistance, dyslipidaemia, and - PMID 41966639
The reviewed literature does not enumerate specific medical contraindications (e.g., pregnancy, malignancy, specific disease states) for CJC-1295. Absence of ap - PMID 42021992
Non-approved peptides including CJC-1295 lack long-term safety data and systematic validation; significant knowledge gaps include optimal dosing regimens and co - PMID 42395176
Potential class-level adverse effects of GH-axis secretagogues include prolactin and cortisol elevations, appetite changes, dysglycaemia, fluid retention, muscu
Frequently asked
Is Mod GRF 1-29 the same as CJC-1295?
Mod GRF 1-29 is CJC-1295 without DAC. Both share the same modified GHRH(1-29) peptide, but CJC-1295 with DAC binds albumin and lasts about a week, while Mod GRF 1-29 lasts about 30 minutes and is dosed one to three times daily.
Is Mod GRF 1-29 the same as sermorelin?
No. Sermorelin is unmodified GHRH(1-29). Mod GRF 1-29 has four amino-acid substitutions that make it more stable and longer-acting than sermorelin, though still short-acting compared with CJC-1295 with DAC.